Anticoagulation in clinical practice -2nd Part: the use of heparins
Keywords:
unfractionated heparin, low-molecular weight heparin, thrombocytopenia, anti Xa activityAbstract
The authors review, in this, the second part of the theme "anticoagulation in clinical practice", the use of heparins in clinical practice. First, the use of unfractionated heparin, is discussed its indicated uses in inpatients, with often consequent long in-patient admission times, as well as the disadvantages of its use on the outpatient basis e.g. difficult use at home and complex monitorisation. Secondly, the authors' present low molecular weight heparins, which combine easy administration with easy monitorisation, making their total cost lower than that of unfractionated heparin. Caution must be exercised in their implementation, as each low molecular weight heparin has an individual profile that must be assessed in each clinical situation. To date, all studies point to a beneficial effect with the use of the various unfractionated heparins in their different clinical settings. lt seems probable that new indications will appear.
Downloads
References
Choay J. Structure and activity of low molecular weight heparins. ln: Christian Doutremepuich. ed. Low molecular weight heparins in clinical practice, Nova Iorque, Mar cel Dekker, inc 1992: 1-6.
Hoppenstead DA, Jeske W, Ahsan A, Walenga JM, Fareed J. Biochemical and pharmacological profile of defined molecular weight fractions of heparin. Seminars in thrombosis and hemostasis 1993; 19( 1): 12-19.
Fareed J. Hoppensteadt DA, Walenga JM. Current pres pectives on low molecular weight heparins. Seminars in thrombosis and hemostasis 1993; 190 ): 1-11.
Handin RJ. Anticoagulant. fibrinolytic and antiplatelet therapy. ln: Isselbacher KJ, 8raunwakl E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principies of Internal Medicine, Nova Iorque. McGraw-Hill. inc 1994: 1810-1813.
Hirsh J. Heparin. N Engl J.Med 1991; 324: 1565-1574.
Morais S, Campos M, Justiça B. Prevenção e tratamento da trombose. Porto: Hospital Geral de Santo António. 1995: 24-25.
Ginsberg JS. Management of venous thromboemholism. N Engl J Med 1996; 335: 1816-1828.
Bergqvist D. Principal view on dose adjustment of low molecular weight heparins. Seminars in thrombosis and hemostasis 1993: 19( 1): 107-110.
Warkentin TE, Levine MN, Hirh J et al. Heparin-induced thrombocytopenia in patients treted with low molecular weight heparins or unfractionated heparins. N Eng! J Med 1995; 332: 1330-1335.
Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Eng! J Med 1995; 332: 1374-1376.
Schmitt Y, Schneider H. Low molecular weight heparin: influence on blood lipids in patients on chronic haemodialisis. Nephrol Dial Transplant 1993; 8: 438-442.
Mardiguian J. Methods of preparation of low molecular weight heparins. In: Christian Doutremepuich ed. Low molecular weight heparins in clinical practice. Nova Iorque, Marcel Dekker, inc 1992: 7-12.
Ofosu FA. Mechanisms of actions of low molecular weight heparin fractions. In: Christian Doutremepuich, ed. Low molecular weight heparins in clinical practice. Nova Iorque, Marcel Dikker. inc 1992: 13-21.
Messmore HL, Wehrmacher WH. Therapeutic use of low molecular weight heparins. Seminars in thrombosis and hemostasis 1993; 19 ( 1): 97-100.
Schafer AI. Low molecular weight heparins-an opportunity for home treatment of venous thrombosis. N Engl J Med 1996; 334 724-725.
Levine M, Gent M, Hirsh J et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for deep-vein thrombosis. N Engl J Med 1996, 334: 677-681.
Vairel EG: Hepanns and fibrinolysis. In: Christian Doutre mepuich, ed. Low molecular weight heparins in clinical practice, Nova Iorque, Marcel Dekker, inc 1992: 51-61.
Fareed J, Jeske W, Eschenfelder V et al. Preclinical studies on a low molecular weight heparin. Thrombosis research, 1996; 81 (Supl )1: S1-S27.
Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698
Barrowdiffe TW: Standardization of assays of low molecular weight heparins. In: Christian Doutremepuich, ed.Low molecular weight heparins in clinical practice, Nova Iorque, Marcel Dekker, inc 1992: 155-169.
Walenga JM. Practical issues on the laboratory monitoring of low molecular weight heparins and related polyssaccharides. Seminars in thrombosis and hemostasis 1993: 19 e n 69-72.
Bouthier J, Kher A, Frapaise FX et al. Some commercial low molecular weight heparins. In: Christian Doutremepuich, ed.Low molecular weight heparins in clinical practice, Nova Iorque, Marcel Dekker, inc 1992: 199-244.
Boisseau MR. Prophylaxis of deep vein thrombosis with low molecular weight heparins. In: Christian Doutremepuich, ed. Low molecular weight heparins in clinical practice, Nova Iorque, Marcel Dekker, inc 1992: 125-136.
Eriksson BI, Kalebo P, Risberg B. Clinical experience of a low molecular weight heparin (Fragmin) in the pre vention of thromboemholism after total hip replacement Seminars in thrombosis and hemostasis 1993; 19 (1 ):122-127.
Bergqvist D. Benoni G, Bjürgell O et al. Low molecular weight heparin (enoxaparin) asptophylaxis against thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
Geerts WH, Jay RM, Code KI, A comparison of low dose heparin with low molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701-707.
The Columbus investigators. Low-molecular-weight heparin in the treatment of patients with venous thrombo embolism. N Engl J Med 1997; 337: 657-662
Simonneau G, Sors H, Charbonnier et al. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669.
Janvier G, Winnack S. Treatment of deep vein thrombosis with low molecular weight heparins. ln: Christian Doutremepuich, ed. Low molecular weight heparins in clinical practice, Nova Iorque, Marcel Dekker, inc 1992: 109-124.
Koopman MMW, Pramloni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996; 334: 682-687.
Breddin HK. Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight heparins? Thrombosis Research 1996; 81 (Supl): S47-S51.
Preisack MB, Karsch KR. Low molecular weight heparins in prevention of restenosis after PTCA. Thromhosis Research 1996; 81 (Supl): S53-S59.
Messmore HL, Wehrmacher WH. Therapeutic use of low molecular weight heparins, Seminars in thrombosis and hemostasis 1993; 19( 1): 97-100.
Vukusich A, Avalos C, Orellana G, et ai. Anticoagulacion en hemodialisis con dosis unica de heparina de bajo peso molecular. Rev Med Chil 1995; 123: 735-741.
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna